The purpose of this guideline is to guide the drug marketing authorization holders (hereinafter referred to as "holders") in China to use MedDRA coding-related medical terms in the work related to post-marketing adverse reaction reporting. Other reporting entities may refer to the ideas and suggestions provided in this guide.
Read more online